GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intech Biopharm Ltd (ROCO:6461) » Definitions » Gross-Profit-to-Asset %

Intech Biopharm (ROCO:6461) Gross-Profit-to-Asset % : -6.73% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Intech Biopharm Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Intech Biopharm's annualized Gross Profit for the quarter that ended in Dec. 2023 was NT$-172.84 Mil. Intech Biopharm's average Total Assets over the quarter that ended in Dec. 2023 was NT$2,566.98 Mil. Therefore, Intech Biopharm's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was -6.73%.


Intech Biopharm Gross-Profit-to-Asset % Historical Data

The historical data trend for Intech Biopharm's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intech Biopharm Gross-Profit-to-Asset % Chart

Intech Biopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.71 -5.31 -4.57 -5.72 -6.23

Intech Biopharm Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.36 -6.23 -6.02 -7.10 -6.73

Competitive Comparison of Intech Biopharm's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Intech Biopharm's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intech Biopharm's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's Gross-Profit-to-Asset % falls into.



Intech Biopharm Gross-Profit-to-Asset % Calculation

Intech Biopharm's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-163.995/( (2550.501+2711.068)/ 2 )
=-163.995/2630.7845
=-6.23 %

Intech Biopharm's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-172.844/( (2422.884+2711.068)/ 2 )
=-172.844/2566.976
=-6.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Intech Biopharm Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Intech Biopharm's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intech Biopharm (ROCO:6461) Business Description

Traded in Other Exchanges
N/A
Address
Ruiguang Road, Neihu District, 3rd Floor, No. 36, Lane 358, Neihu, Taipei, TWN
Intech Biopharm Ltd is a biotechnology company. The company develops inhalation products including single or combination generic products and some new combinations or new formulation projects are under development. It develops drugs for the treatment of lung diseases such as asthma.

Intech Biopharm (ROCO:6461) Headlines

No Headlines